PT-141

PT-141 works through a completely different mechanism than PDE5 inhibitors like Viagra (sildenafil) or Cialis (tadalafil). While PDE5 inhibitors work on blood vessels to improve erection by enhancing blood flow, PT-141 works in the central nervous system by activating melanocortin receptors in the hypothalamus to enhance sexual desire itself. This makes PT-141 a potential option for individuals who don't respond to PDE5 inhibitors, as it addresses the psychological/neurological component of sexual function rather than just the physical response.

Two identical Phase 3 trials (RECONNECT) enrolled 1,247 premenopausal women with hypoactive sexual desire disorder. Women received bremelanotide 1.75 mg subcutaneously as needed for 24 weeks. Both studies showed statistically significant improvements in sexual desire (measured by FSFI-D: +0.30 to +0.42 points, P<.001) and significant reductions in distress related to low sexual desire (FSDS-DAO: -0.29 to -0.37 points, P<.005) compared to placebo. These results led to FDA approval in June 2019.

PT-141 is FDA-approved only for premenopausal women with HSDD (as Vyleesi). It is not approved for use in men. However, it has been studied in men with erectile dysfunction, including those who did not respond to PDE5 inhibitors, and showed efficacy through its CNS mechanism. For men, PT-141 remains a research compound and is not FDA-approved for any male indication.

The most common side effects in clinical trials were nausea (40%), flushing (20%), injection site reactions (13%), and headache (11%). Most adverse events were mild to moderate. PT-141 may also cause temporary increases in blood pressure and decreases in heart rate, which is why it's contraindicated in uncontrolled hypertension. Focal hyperpigmentation (skin darkening) has also been reported and may not fully resolve after stopping treatment.

PT-141 typically begins working within 45–60 minutes after subcutaneous injection, with peak effects occurring around 2 hours. The effects may last up to 24 hours. This is why it's recommended to administer the injection at least 45 minutes before anticipated sexual activity. The half-life is approximately 2.7 hours.

Yes, PT-141 can cause focal hyperpigmentation (darkening of skin), though this effect is less pronounced than with Melanotan II. In clinical trials, hyperpigmentation of the face, gums, and breasts was reported. This darkening may not fully resolve after discontinuing the medication. If you develop new or worsening dark spots while using PT-141, you should consult a healthcare provider.